Everyday Health on MSN
Novel targeted therapies for IgAN: What you need to know
Explore novel therapies for IgA nephropathy that target inflammation and antibody production. Learn how these advancements ...
Today, the American Kidney Fund (AKF) and the IgA Nephrology Foundation announce the creation of a new resource for IgA nephropathy patients and their loved ones: the IgA nephropathy patient ...
IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, has an estimated incidence of 0.2-5 per 100,000 ...
Living with the rare condition of IgA nephropathy can feel lonely. Patient advocate Stuart Miller shares his treatment journey and how to stay connected with those who understand. Share on Pinterest ...
MedPage Today on MSN
First-in-class drug approved for IgA nephropathy
It has not been established whether atacicept slows kidney function decline long-term, how ...
Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial ...
After an IgA nephropathy (IgAN) diagnosis, your care team has likely discussed different treatment options with you, including some newer targeted therapies such as targeted-release budesonide or ...
Explore emerging IgA nephropathy therapies—complement and BAFF/APRIL inhibitors, targeted budesonide—and why long‑term safety data still lags. How have the KDIGO thresholds from proteinuria changed ...
Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...
New KDIGO updates push earlier IgA nephropathy treatment, targeting immune pathways and nephron protection to cut proteinuria and slow eGFR decline. How do histologic features (e.g., Oxford MEST-C ...
HOUSTON — Atacicept, an investigational dual B-cell activating factor and a proliferation-inducing ligand (BAFF/APRIL) inhibitor, showed substantial reductions of proteinuria and benefits in other ...
Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results